Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 1: Appropriate Identification of Candidates for and Practical Implementation of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Aditya Bardia, MD, MPH
Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH
Posted on 04/30/2026